Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection.

ABSTRACT:

Introduction

Tenofovir alafenamide (TAF), a prodrug of tenofovir, achieves higher intracellular concentrations of tenofovir-diphosphate and 90% lower plasma concentrations of tenofovir compared to tenofovir disoproxil fumarate (TDF). TAF is associated with improved renal and bone safety outcomes.

Areas covered

We review the efficacy and safety of TAF-containing regimens in adults and pediatrics. We highlight safety data during pregnancy, drug interactions during co-administration with tuberculosis treatment, and critical knowledge gaps to be addressed for the successful implementation of TAF in low- and middle-income countries. We performed a search on MEDLINE PubMed and conference websites for relevant articles published from January 2010 to March 2023.

Expert opinion

SUBMITTER: Osuala EC 

PROVIDER: S-EPMC10613124 | biostudies-literature | 2023 Jul-Dec

REPOSITORIES: biostudies-literature